Zydus Pharmaceuticals Inc, USA, a 100 percent subsidiary of Cadila Healthcare (Zydus Cadila), has signed a license and supply agreement with CHEMI SpA of Italy, a subsidiary of Italfarmaco Group, to launch the generic equivalent of Sanofi Aventis’s branded product Lovenox® (Enoxaparin Sodium Injection).
The company will launch the drug in seven dosage strengths in the United States.
“Under the agreement, CHEMI will manufacture and supply the Enoxaparin Sodium Injection which Zydus will commercialize in the US. CHEMI owns proprietary rights on a pharmaceutical product composed of Enoxaparin Sodium (Preservative Free) single-use pre-filled syringes, which is an APrated generic version of the branded product Lovenox,” said Cadila in its BSE filing.
News Source:- Moneycontrol